Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) EBIT (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBIT for 9 consecutive years, with $39.6 million as the latest value for Q4 2025.

  • Quarterly EBIT changed N/A to $39.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $9.4 million for FY2025, 105.02% up from the prior year.
  • EBIT for Q4 2025 was $39.6 million at Soleno Therapeutics, up from $22.1 million in the prior quarter.
  • The five-year high for EBIT was $39.6 million in Q4 2025, with the low at -$45.7 million in Q1 2025.